Adalimumab (Humira) is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration for the trea™ent of patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, chronic psoriasis, hidradenitis suppurativa, and juvenile idiopathic arthritis. Adalimumab binds to the TNFa (tumor necrosis factor-alpha), and blocks its interaction with TNFa receptors, reducing the inflammatory response of autoimmune diseases.
GenScript Anti-Adalimumab Antibody, pAb, Rabbit is produced from sera of a rabbit immunized with Adalimumab.